Gilead Sciences launches Trodelvy in TNBC, shares hold near $128

Gilead Sciences is back in focus after the FDA approved Trodelvy for two TNBC indications on June 25. The shares closed at $127.86 on June 26, and Davy showed a 20-minute delayed quote on Sunday morning.

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-28, 12:35.

Gilead Sciences (US3755581036) is trading around its latest FDA-driven catalyst in New York. The agency approved Trodelvy for two triple-negative breast cancer indications on June 25, according to a Yahoo Finance report that cites the company announcement.

FDA approval in detail

The approval covers sacituzumab govitecan-hziy as a single-agent first-line treatment for certain adults with unresectable locally advanced or metastatic TNBC, and a combination use with Merck's Keytruda in another first-line setting. Yahoo Finance quoted the June 25 FDA decision and Gilead's June 23 European Commission authorization for Trodelvy as background to the broader launch sequence.Yahoo Finance report on the FDA decision

Trodelvy is Gilead's antibody-drug conjugate for advanced breast cancer, and the recent approvals widen its addressable patient pool in the United States and Europe. The sequence matters because the drug already received European marketing authorization on June 23, two days before the FDA step.

New York price and peer set

Gilead Sciences shares closed at $127.86 on Friday, June 26, with MarketBeat showing a $127.40 extended-trading print later that evening. Davy's quote page listed the same $127.88 level at 01:30 AM on June 28, 2026, while TradingKey placed the stock between support at $120.45 and resistance at $136.26.MarketBeat quote and news page

In the U.S. healthcare peer group, Gilead sits alongside Merck, Pfizer and Amgen on the NASDAQ. TradingKey's technical page for GILD also described four buy signals and one sell signal, with a momentum score of 7.32.TradingKey technical analysis for GILD

Trodelvy in the portfolio

Trodelvy is the representative product at the center of this weekend's Gilead discussion. The drug is an antibody-drug conjugate used in triple-negative breast cancer, and the new U.S. approval adds to a recent European marketing authorization.

Gilead shares on NASDAQ

The Gilead Sciences shares (US3755581036) trade on June 28, 2026, at 12:35 UTC on NASDAQ at $127.88.

Gilead Sciences at a glance

• Company: Gilead Sciences, Inc.
• ISIN: US3755581036
• Ticker: GILD
• Trading venue: NASDAQ
• Price (as of 2026-06-28, 12:35): 127.88 USD
• Sector / industry: Health Care / Biotechnology
• Index membership: S&P 500

Disclaimer: This article is for information only and does not constitute investment advice.